Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667, In Patients With Dermatomyositis
Portfolio Pulse from Benzinga Newsdesk
Galapagos has announced the start of a Phase 2 study with its selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis. This marks a significant step in the development of the drug.
May 23, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galapagos has initiated a Phase 2 study for its selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis, potentially leading to positive outcomes for the company.
The initiation of the Phase 2 study for GLPG3667 is a significant milestone in the drug's development process. Positive results from this study could lead to increased investor confidence in Galapagos and potentially boost its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100